-
A New Frontier: FDA Approves Imfinzi for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
A Significant Breakthrough in Bladder Cancer Care For patients facing non-muscle invasive bladder cancer (NMIBC), treatment options have historically been limited, particularly for those whose cancer does not respond to standard BCG therapy. Recently, the landscape of care shifted with the FDA approval of Imfinzi (durvalumab), marking a major milestone as the first and only…
-
A Breakthrough in Diabetes Care: Afrezza Approved for Children and Adolescents
A New Chapter for Pediatric Diabetes Management For many families managing diabetes, the daily routine of injections can be a significant source of stress and discomfort. MannKind Corporation has recently reached a major milestone in diabetes treatment: the FDA has officially approved Afrezza (insulin human) inhalation powder for use in children and adolescents with diabetes.…
-
New Hope Against Resistant UTIs: FDA Approves Zaynich
A Breakthrough in Antibiotic Treatment The landscape for treating severe infections just got a new, powerful tool. The FDA has officially approved Zaynich, a combination antibiotic consisting of cefepime and zidebactam, designed specifically to treat complicated urinary tract infections (cUTIs), including pyelonephritis, in adults. Why This Approval Matters As antibiotic resistance continues to grow, healthcare…
-
FDA Approves Groundbreaking All-Oral, Fixed-Duration Treatment for Previously Untreated CLL
NYSE: $ABBV A Significant Advance in Chronic Lymphocytic Leukemia Treatment The U.S. Food and Drug Administration (FDA) has granted approval for the combination treatment of VENCLEXTA® (venetoclax) and acalabrutinib for adult patients newly diagnosed with chronic lymphocytic leukemia (CLL). This pivotal decision, supported by robust data from the Phase 3 AMPLIFY trial, introduces the first…
-
FDA Greenlights FILKRI™: Accord BioPharma Completes Comprehensive G-CSF Portfolio for Oncology Support
Accord BioPharma Secures FDA Approval for FILKRI™ (filgrastim-laha), Biosimilar to NEUPOGEN® Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., has announced a significant milestone: the U.S. Food and Drug Administration (FDA) has approved FILKRI™ (filgrastim-laha). This product is a biosimilar to the established reference product, NEUPOGEN® (filgrastim). The approval, announced on February 17,…
-
Significant Clinical Milestone: FDA Acknowledges Positive Outcomes for Rexlemestrocel-L in Chronic Back Pain Management
NASDAQ: $MESO A Promising Advancement in Treating Chronic Back Pain The recent announcement from Mesoblast regarding the clinical data for Rexlemestrocel-L represents a noteworthy step forward in addressing the pervasive challenge of chronic back pain. According to the news release dated January 19, 2026, the U.S. Food and Drug Administration (FDA) has formally acknowledged the…
-
Big News for APDS: FDA Grants Priority Review for Leniolisib in Younger Children
NASDAQ: $PHAR Pharming Group has just shared exciting developments regarding their treatment for Activated PI3K-delta Syndrome (APDS). The U.S. Food and Drug Administration (FDA) has formally accepted the supplemental New Drug Application (sNDA) for leniolisib and, significantly, granted it Priority Review status. This is a pivotal moment for the APDS community, particularly for families managing…
-
Aquestive Therapeutics: A Significant Step Forward in Regulatory Development
NASDAQ: $AQST Investors and stakeholders interested in the pharmaceutical landscape have a compelling reason to examine the latest announcement from Aquestive Therapeutics. The news signals a crucial milestone in the company’s journey toward bringing innovative therapies to market. Understanding the Context of the Announcement Aquestive Therapeutics operates within the specialized field of pharmaceutics, often focusing…
-
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
NASDAQ: $CKPT Introduction Checkpoint Therapeutics, a leading biopharmaceutical company, recently made a significant announcement regarding the FDA acceptance of the Biologics License Application (BLA) resubmission of Cosibelimab for the treatment of advanced cutaneous squamous cell carcinoma. This development marks a crucial milestone in the ongoing efforts to provide effective treatment options for patients battling this…
-
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine; PDUFA goal date is January 31 2025
NASDAQ: $AXSM Axsome Therapeutics, a leading biopharmaceutical company, has recently announced the exciting news that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for AXS-07 for the acute treatment of migraine. With the FDA acceptance of the NDA resubmission, Axsome Therapeutics is one step closer to…
-
BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device
NYSE: $BDX 1. Introduction: Overview of BD’s FDA 510(k) Clearance for Potentially Transformative Fingertip Collection Device The field of sample collection in healthcare is about to witness a significant transformation with the recent FDA 510(k) clearance obtained by BD for their groundbreaking fingertip collection device. This innovative device offers a convenient and user-friendly alternative to…
-
Calliditas Therapeutics | The FDA Decision To Convert The Accelerated Approval of Calliditas Therapeutics’ Tarpeyo To Full Approval, December 20, 2023
NASDAQ: CALT 1. Introduction to Calliditas Therapeutics and Tarpeyo Calliditas Therapeutics is a renowned pharmaceutical company focused on developing innovative therapies to address unmet medical needs. One of their notable products is Tarpeyo, a drug designed to provide significant benefits to patients suffering from a specific medical condition. The accelerated approval granted by the FDA…
-
Vanda Pharmaceuticals | Announces U.S. FDA Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
NASDAQ: VNDA 1. Introduction to Vanda Pharmaceuticals’ new drug application for Tradipitant Vanda Pharmaceuticals, a leading biopharmaceutical company, has recently announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Tradipitant, a potential breakthrough treatment for gastroparesis. This acceptance marks a significant milestone in Vanda Pharmaceuticals’ efforts…
-
Soligenix | Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet’s Disease
NASDAQ: SNGX Introduction to Soligenix’s Phase 2 Clinical Trial Soligenix, a biopharmaceutical company focused on developing innovative therapies, has recently received FDA Investigational New Drug (IND) clearance for the Phase 2 clinical trial of Dusquetide in the treatment of aphthous ulcers in Behçets Disease. This clearance marks a significant milestone in the development of potential…
-
Carisma Therapeutics | Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
NASDAQ: CARM Carisma Therapeutics, a leading biotechnology company committed to developing innovative cancer treatments, recently made a groundbreaking announcement. The company has successfully obtained clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. This is a significant milestone for Carisma Therapeutics, as it paves the way for the…
-
BrainStorm Cell Therapeutics | Announces FDA Advisory Committee Meeting to Review NurOwn® PDUFA Target Action Date Scheduled for December 8, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced that the US FDA has granted the company a meeting to discuss the regulatory path forward for NurOwn® in ALS. The meeting, scheduled for December 6, 2023, will focus on plans for a Special Protocol Assessment (SPA) for a confirmatory Phase 3 trial in ALS. BrainStorm aims to…
-
Arcutis Biotherapeutics | FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
NASDAQ: ARQT WESTLAKE VILLAGE, Calif., April 18, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application (NDA) for roflumilast foam 0.3% for the treatment of seborrheic…
-
Rocket Pharmaceuticals | Unlocking the Potential: RP-L201 and its FDA Designations – A Breakthrough in Pediatric Medicine
NASDAQ: RCKT Rocket Pharmaceuticals has achieved significant milestones with their groundbreaking therapy, RP-L201. The FDA has granted several prestigious designations to RP-L201, including Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric, Fast Track, and Orphan Drug designations. These designations highlight the immense potential of RP-L201 in treating pediatric patients and emphasize the urgent need for innovative…
-
Aquestive Therapeutics | FDA Acceptance of Libervant™ for Treatment of Seizure Clusters in Young Patients
NASDAQ: AQST The FDA has recently accepted the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film, aiming to tackle the treatment of seizure clusters in children between the ages of two and five. This development provides hope for young patients and their families who have pbeen struggling with the challenges of managing seizure clusters.…